코아스템켐온

166480KOSDAQ의약품 제조업

40.3 / 100

Reference Date: 2026-04-13

Financial Score4.5 / 40

News Sentiment18.8 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Declined 8.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CoaStemKemOn focuses on developing and selling stem cell therapies, with its product 'NeuroNata-Al' for Lou Gehrig's disease commercialized since 2015. The company merged with KemOn, a top non-clinical CRO firm in South Korea, in 2022 to enhance R&D capabilities, and approximately 98% of its revenue comes from non-clinical research services.

Number of Employees

321people

Average Salary

48.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

2.36Industry Average 1.040.0Point

2.3x industry avg (risky)

ROE

-51.72Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

36.21Industry Average 11.980.0Point

3.0x industry avg (risky)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼22.2% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼4.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -63.1% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 75

Positive
코아스템켐온, 해수부 국책과제 선정…비임상 안전성 평가 수행
코아스템켐온은 해양수산부 주관 국책과제에 공동연구기관으로 선정되어 해양 유래 기능성 소재의 비임상 안전성 데이터 확보를 담당한다.
Positive
코아스템켐온, 관리종목 리스크 해소…뉴로나타 알, 허가 대기
코아스템켐온은 2년 연속 법차손 비율이 관리종목 지정 기준을 하회하며 관리종목 리스크를 해소했고, 뉴로나타 알의 국내 허가도 대기 중이다.

Detailed Momentum

52-week position5.0Point

52w mid range (48%)

Current 2,460Won52-week high 3,97552-week low 1,060

1-month return1.0Point

1m -8.89% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-01
Neutral[기재정정]주식매수선택권부여에관한신고2026-03-30
Neutral정기주주총회결과2026-03-27
Neutral감사보고서제출2026-03-19
Neutral사업보고서 (2025.12)2026-03-19